コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 tolic dysfunction, diastolic dysfunction, or left atrial enlargement).
2 cular hypertrophy and a higher prevalence of left atrial enlargement.
3 ion expressed as ventricular hypertrophy and left atrial enlargement.
4 endent of traditional risk factors including left atrial enlargement.
5 to increasing obesity, which correlates with left atrial enlargement.
6 ggesting functional MR can also be caused by left atrial enlargement.
7 , followed by diastolic dysfunction (21.3%), left atrial enlargement (15.3%), systolic dysfunction (6
8 .26 [95% CI, 1.45-3.53]), moderate to severe left atrial enlargement (2 points; OR, 3.43 [95% CI, 2.4
10 ive physiology, characterized by progressive left atrial enlargement and diastolic dysfunction with p
11 Atrial arrhythmias may reflect underlying left atrial enlargement and diastolic dysfunction, which
12 e find evidence supporting a causal role for left atrial enlargement and dysfunction on atrial fibril
14 d age, female sex, greater right atrial than left atrial enlargement and lower systolic pulmonary art
15 Clinical evaluation revealed the presence of left atrial enlargement and marked left ventricle diasto
18 In the total population, the prevalence of left atrial enlargement and the association between card
19 without HCM diagnoses had clear evidence of left atrial enlargement and/or septal/LV hypertrophy on
20 r hypercontractility, diastolic dysfunction, left-atrial enlargement and left ventricular fibrosis, a
21 traditionally have been used as markers for left atrial enlargement, and both have been associated w
22 tion concomitant with diastolic dysfunction, left atrial enlargement, and cardiac hypertrophy with a
23 alls, decreased left ventricular dimensions, left atrial enlargement, and hyperdynamic left ventricul
25 inflammation, left ventricular hypertrophy, left atrial enlargement, and subclinical left ventricula
26 ensates for increasing regurgitant volume by left-atrial enlargement, causes left-ventricular overloa
27 ic Csk knockout in mice led to increased AF, left atrial enlargement, fibrosis, and inflammation, phe
31 e full spectrum of diagnoses associated with left atrial enlargement in sex-stratified clinical popul
32 , including left ventricular hypertrophy and left atrial enlargement, in addition to pulmonary hypert
38 ), isolated LV diastolic dysfunction (LVDD), left atrial enlargement (LAE), LV hypertrophy (LVH), and
39 on: HR, 6.64; 95% CI, 2.29-19.24; P < .001), left atrial enlargement (LAE; HR, 3.63; 95% CI, 1.55-8.4
41 estrictive: 1 echocardiographic abnormality (left atrial enlargement, left ventricle hypertrophy, dia
42 hy-based diabetic cardiomyopathy (echo-DbCM; left atrial enlargement, left ventricular hypertrophy, o
43 rutinib for 4 weeks results in inducible AF, left atrial enlargement, myocardial fibrosis, and inflam
45 moderate or greater mitral regurgitation or left atrial enlargement or atrial fibrillation (stage 2)
47 etely independent of age, hypertension, sex, left atrial enlargement, valvular heart disease, left ve
48 nce of LV hypertrophy was 21%, prevalence of left atrial enlargement was 83%, prevalence of elevated